Medication info
Esomeprazole Magnesium Trihydrate 40 mg Tablet

Esomeprazole Magnesium Trihydrate 40 mg Tablet

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›43.38mg / 1 tablet
Manufacturer / importer
Ilhwa Co., Ltd.
Appearance
Pink oblong film-coated tablet
Packaging
28 tablets/box [(7 tablets/Alu-Alu x 4)]
Approval status
Active

MFDS item code 201804136 · Approved 2018.10.19 · Insurance code 640903710

Summary

Main use
Treatment of acid-related disorders (reflux, ulcers, etc.), Helicobacter pylori eradication, and gastrointestinal disorders caused by anti-inflammatory analgesics
Who uses it
Adults · Children
Adult dosage
This drug should be swallowed with a liquid such as water; do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. · Once symptoms are relieved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. Clinical trials exceeding 4 weeks have not been conducted. 4) Patients requiring continued nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. According to clinical data, most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into two doses. 6) Maintenance therapy following intravenous induction to prevent rebleeding due to gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction to prevent rebleeding due to gastric or duodenal ulcers. 4. Renal impairment No dose adjustment is necessary. Since experience with administration to patients with severe renal failure is limited, administer with caution. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed a dose of 20 mg of this drug. 6. Older adults No dose adjustment is necessary.
Children's dosage
2. Adolescents 12 years of age and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. · Once symptoms are relieved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 3. Children under 12 years of age There is no experience with administration of this drug to children under 12 years of age.

Ingredients

Manufacturer
Ilhwa Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders (reflux, ulcers, etc.), Helicobacter pylori eradication, and gastrointestinal disorders caused by anti-inflammatory analgesics

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • duodenal ulcer
  • peptic ulcer
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcer
  • duodenal ulcer
  • Zollinger-Ellison syndrome
  • rebleeding of gastric ulcer
View approved original text

This medication is used as maintenance therapy for the treatment and prevention of gastroesophageal reflux disease and esophagitis. It is also effective for the treatment and prevention of recurrence of duodenal ulcers and peptic ulcers as a part of a combination therapy to eliminate Helicobacter pylori. It helps in the short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug use and is used for treatment of gastric ulcers and prevention of gastric/duodenal ulcers in patients on continuous analgesics. It is also effective for the treatment of Zollinger-Ellison syndrome and the maintenance therapy for the prevention of rebleeding of gastric/duodenal ulcers. Overall, it is used for the treatment and prevention of various gastrointestinal-related diseases.

Dosage and Administration

Adult dosage

This drug should be swallowed with a liquid such as water; do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. · Once symptoms are relieved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. Clinical trials exceeding 4 weeks have not been conducted. 4) Patients requiring continued nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. According to clinical data, most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into two doses. 6) Maintenance therapy following intravenous induction to prevent rebleeding due to gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction to prevent rebleeding due to gastric or duodenal ulcers. 4. Renal impairment No dose adjustment is necessary. Since experience with administration to patients with severe renal failure is limited, administer with caution. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed a dose of 20 mg of this drug. 6. Older adults No dose adjustment is necessary.

Children's dosage

2. Adolescents 12 years of age and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. · Once symptoms are relieved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 3. Children under 12 years of age There is no experience with administration of this drug to children under 12 years of age.

Precautions

This medication should not be administered to certain patients. Patients with allergies or a history of hypersensitivity to this medication, its ingredients, or benzimidazole derivatives should not use it. Furthermore, patients allergic to penicillin antibiotics or macrolide antibiotics should not be treated with amoxicillin or clarithromycin when used in conjunction with this medication for the eradication of Helicobacter pylori. Additionally, patients taking specific cardiac medications or antivirals, nursing mothers, and those with a history of myocardial infarction should ideally not use this medication. This medication may cause a variety of adverse reactions. The most common symptoms include headache, abdominal pain, diarrhea, constipation, nausea, and vomiting, and sometimes dizziness or insomnia as neurological symptoms may appear. Rarely, blood disorders, liver dysfunction, severe allergic reactions, skin rashes, hair loss, muscle weakness, and nephritis have been reported. Additionally, hypomagnesemia may develop, so magnesium levels should be monitored regularly during long-term use. This medication can obscure symptoms of malignant tumors or delay diagnosis; therefore, in gastric ulcer patients with warning signs such as weight loss, recurrent vomiting, hematemesis, or melena, malignancy must be ruled out. Regular examinations are necessary during long-term use, especially if taken for more than 1 year; any changes in symptoms should prompt immediate consultation with a physician. This medication suppresses gastric acid secretion and may increase bacterial growth in the gastrointestinal tract, so if diarrhea persists, the possibility of Clostridium difficile infection should be considered. Also, long-term use may increase the risk of fractures, so patients at risk for osteoporosis should be carefully monitored. Due to potential drug interactions, especially with antibiotics, antivirals, anticoagulants, anticonvulsants, immunosuppressants, and some antidepressants, consultation with a physician or pharmacist is necessary when combined with this medication. Changing blood concentrations of some drugs may occur with this medication, so monitoring the status of medications being taken is important. Data on the safety of this medication during pregnancy are limited, so caution is advised when taken by pregnant women, and nursing mothers are generally advised not to take this medication. In case of overdose, there is no specific antidote, and symptomatic treatment should be initiated, keeping the medication out of reach of children. It is also crucial to preserve the medication in its original packaging and not transfer it to other containers to maintain its quality.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, confusion, depression, aggression, hallucination, headache, dizziness, paresthesia, drowsiness, taste disturbance, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized pustular psoriasis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, weakness, increased sweating, Clostridium difficile associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, substernal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, goiter, irritable bowel syndrome, constipation exacerbation, dyspepsia, dysphagia, gastrointestinal malabsorption, epigastric pain, belching, esophageal disorder, frequent bowel movements, gastritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue edema, ulcerative stomatitis, vomiting, earache, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver function abnormalities, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, thirst, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, convulsions, fibromyalgia syndrome, hernia, rheumatoid polymyositis, arthralgia, anorexia, apathy, increased appetite, confusion, worsening depression, hypertonicity, anxiety, sensory impairment, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremors, dizziness, visual field defects, paresthesia, drowsiness, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, rash, erythematous rash, papular rash, angioedema, dermatitis, itching, urticaria, increased sweating, otitis media, abnormal olfaction, taste loss, taste distortion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urination frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, hypocalcemia, hypokalemia, rhabdomyolysis, myalgia, elevated creatine kinase, increased serum and urinary myoglobin

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a sealed container. It is recommended to maintain a storage temperature between 1°C and 30°C (room temperature). This helps to preserve the effectiveness of the medication for a longer time.

Appearance and packaging

Appearance

Pink oblong film-coated tablet

Package unit

28 tablets/box [(7 tablets/Alu-Alu x 4)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.